The NAVIGATE ESUS [New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (ESUS)] trial showed that in patients with an ESUS, there was no significant difference in stroke recurrence between the rivaroxaban and aspirin groups (34). This evidence concerns the gene TNXA and Stroke.